Q3 2025 Palatin Technologies Inc Earnings Call Transcript
Key Points
- Palatin Technologies Inc (PTNT) reported positive top-line data for their Phase 2 study, demonstrating significant weight loss with the co-administration of melanocortin 4 receptor agonist bremelanotide and tirzepatide.
- The company achieved a significant reduction in operating expenses, decreasing from $9.2 million to $4.8 million compared to the previous year.
- Palatin Technologies Inc (PTNT) reported a decrease in net loss from $8.4 million to $4.8 million year-over-year, primarily due to reduced operating expenses.
- The FDA granted orphan drug status to PL7737 for treating obesity due to leptin receptor deficiency, with plans for an initial new drug application submission in early 2026.
- Positive Phase 2 study results for PL8177 in treating ulcerative colitis showed significant clinical remission and response rates, enhancing business development discussions with potential partners.
- Palatin Technologies Inc (PTNT) faced suspension of its common stock trading on the NYSE American Stock Exchange due to low selling prices, now trading on the OTC Pink Market.
- The company did not record any product sales for the quarter ended March 31, 2025, following the sale of Vyleesi's worldwide rights.
- Cash and cash equivalents significantly decreased from $9.5 million to $2.5 million as of March 31, 2025, indicating a need for additional funding.
- Palatin Technologies Inc (PTNT) is actively seeking multiple potential funding sources to meet future operating cash requirements.
- The company faces challenges in addressing the NYSE's decision to de-list its common stock, which could impact investor confidence.
Greetings. Welcome to Palatin's third-quarter fiscal year 2025 operating results conference call. (Operator Instructions) As a reminder, this conference call is being recorded.
Before we begin our remarks, I would like to remind you that statements made by Palatin are not historical facts and may be forward-looking statements. These statements are based on assumptions that may or may not prove to be accurate and that the actual results may differ materially from those anticipated due to the variety of risks and uncertainties discussed in the company's most recent filings with the Securities and Exchange Commission. Please consider such risks and uncertainties carefully in evaluating these forward-looking statements by Palatin's prospects.
Now, I would like to turn the call over to our host, Dr. Carl Spana, President and Chief Executive Officer of Palatin. Please go ahead.
Thank you. Good morning and welcome to the Palatin third-quarter fiscal year 2025 call. I
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
